Home › Cancro ovarico › Tennessee
Studi clinici su Cancro ovarico nello stato di Tennessee
55 studi su Cancro ovarico cercano partecipanti presso sedi nello stato di Tennessee.
Città nello stato di Tennessee
Testo ufficiale dello studio (inglese)
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Erlanger Health, Chattanooga
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 5 ott 2026 · NCT06915025Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- Vanderbilt University/Ingram Cancer Center, Nashville
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 ott 2026 · NCT07001748Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Regional Cancer Center at Johnson City Medical Center, Johnson City
- Ballad Health Cancer Care - Kingsport, Kingsport
- e altri 3
In reclutamentoFase 2
Tutte le età · Tutti i sessi · Aggiornato il 5 ott 2026 · NCT05564377A Study of PHST001 in Advanced Solid Tumors
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 ott 2026 · NCT06840886A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Tennessee Oncology, Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06270706A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06465069The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Sarah Cannon Research Institute, Nashville
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04585750A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- SCRI Oncology Partners, Nashville
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06760819A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- SCRI Oncology Partners, Nashville
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06172478A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Sarah Cannon Research Institute (SCRI), Nashville
In reclutamentoFase 1
Età 19 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06586957A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- SCRI Oncology Partners /ID# 279733, Nashville
In reclutamentoFase 2
Età 18 e oltre · Donne · Aggiornato il 1 ott 2026 · NCT07024784First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- SCRI Oncology Partners, Nashville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT06799065A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT05877599DESTINY-PANTUMOUR04
- Research Site, Nashville
In reclutamentoStudio osservazionale
Età da 18 a 130 · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07124000Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Vanderbilt University Medical Center, Nashville
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT04981119Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Nashville
In reclutamentoFase 2
Età da 18 a 130 · Tutti i sessi · Aggiornato il 23 set 2026 · NCT05489211A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Vanderbilt University Medical Center, Nashville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07213804A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- University Of Tennessee Medical Center /ID# 278225, Knoxville
In reclutamentoFase 2
Età 18 e oltre · Donne · Aggiornato il 22 set 2026 · NCT07059845Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Sarah Cannon Research Institue, Nashville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06128551Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Sarah Cannon - Tennessee Oncology, Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT05983432A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- West Cancer Center and Research Institute ( Site 0013), Germantown
- University of Tennessee Medical Center ( Site 0087), Knoxville
- Henry-Joyce Cancer Clinic ( Site 0011), Nashville
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 17 set 2026 · NCT07318558A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Sarah Cannon Nashville, Nashville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07109726Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Erlanger Health, Inc., Chattanooga
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 15 set 2026 · NCT07214779Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Sarah Cannon Research Institute, Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 set 2026 · NCT06293898Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
- Sarah Cannon Research Institute, Nashville
In reclutamentoFase 1
Età 18 e oltre · Donne · Aggiornato il 3 set 2026 · NCT07755436A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Henry-Joyce Cancer Clinic ( Site 0060), Nashville
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 3 set 2026 · NCT06824467Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- Erlanger Health, Inc., Chattanooga
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 26 ago 2026 · NCT05281471Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
In reclutamentoFase 1
Età 15 e oltre · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT06276491Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Saint Jude Children's Research Hospital, Memphis
In reclutamentoFase 1/2
12 Months – 30 Years · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT04851119A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 ago 2026 · NCT07182149A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Vanderbilt University Medical Center, Nashville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT04895709A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Vanderbilt-Ingram Cancer Center at Franklin, Franklin
- Vanderbilt-Ingram Cancer Center Cool Springs, Franklin
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- e altri 1
In reclutamento
Età da 35 a 50 · Donne · Aggiornato il 7 ago 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Vanderbilt-Ingram Cancer Center at Franklin, Franklin
- Vanderbilt-Ingram Cancer Center Cool Springs, Franklin
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 7 ago 2026 · NCT06580314A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Erlanger Health, Inc, Chattanooga
- The West Clinic, Germantown
- SCRI Oncology Partners, Nashville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 ago 2026 · NCT06330064Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville
- Tennessee Oncology, Nashville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 ago 2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Tennessee Oncology, PLLC, Chattanooga
- SCRI Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 lug 2026 · NCT04657068A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- SCRI - TriStar Medical Group Children's Specialists, Nashville
- SCRI Oncology Partners, Nashville
In reclutamentoFase 2
Età 8 e oltre · Tutti i sessi · Aggiornato il 27 lug 2026 · NCT05503797Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #102, Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 lug 2026 · NCT06545942A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- SCRI Oncology Partners, Nashville
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 lug 2026 · NCT06695845First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- The West Clinic, PLLC dba West Cancer Center, Germantown
- Sarah Cannon Research Institute, Nashville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 7 lug 2026 · NCT05768139Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.